Skip to content
10-Q

Quarterly Report

Oruka Therapeutics, Inc. ORKA

0001213900-26-055769

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 60.31M sh
Capex Q1 2026 · Mar 31, 2026 $73K
Capex Q1 2026 · Mar 31, 2025 $13K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$23.58M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$20.87M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $49.52M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $46.94M
Stockholders Equity Q1 2026 · Mar 31, 2026 $486.72M
Stockholders Equity Q1 2026 · Dec 31, 2025 $471.93M
Stockholders Equity Q1 2026 · Mar 31, 2025 $364.73M
Stockholders Equity Q1 2026 · Dec 31, 2024 $382.22M
Current Liabilities Q1 2026 · Mar 31, 2026 $16.63M
Current Liabilities Q1 2026 · Dec 31, 2025 $15.37M
Total Liabilities Q1 2026 · Mar 31, 2026 $17.76M
Total Liabilities Q1 2026 · Dec 31, 2025 $16.69M
Current Assets Q1 2026 · Mar 31, 2026 $395.25M
Current Assets Q1 2026 · Dec 31, 2025 $343.86M
Total Assets Q1 2026 · Mar 31, 2026 $504.48M
Total Assets Q1 2026 · Dec 31, 2025 $488.62M
Rd Expense Q1 2026 · Mar 31, 2026 $29.15M
Rd Expense Q1 2026 · Mar 31, 2025 $19.93M
Net Income Q1 2026 · Mar 31, 2026 −$31.82M
Net Income Q1 2026 · Mar 31, 2025 −$21M
Operating Income Q1 2026 · Mar 31, 2026 −$36.43M
Operating Income Q1 2026 · Mar 31, 2025 −$25.09M